QCM
RXRX icon

Quantinno Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Quantinno Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,328
Closed -$31.7K – 3506
2026
Q1 		$31.7K Sell
10,328
-43,871
-81% -$170K ﹤0.01% 3291
2025
Q4 		$222K Buy
54,199
+24,460
+82% +$121K ﹤0.01% 3012
2025
Q3 		$145K Buy
+29,739
New +$156K ﹤0.01% 2837
2025
Q2 		– Sell
-19,296
Closed -$102K – 2622
2025
Q1 		$102K Buy
+19,296
New +$141K ﹤0.01% 2029

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Quantinno Capital Management's RXRX Position: Q2 2026 in Review

Quantinno Capital Management sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 10,328 shares — an estimated $31.7K sold.

Quantinno Capital Management first reported a position in RXRX in Q1 2025 and held it in 4 quarters. The position peaked at $222K in Q4 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Quantinno Capital Management reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Quantinno Capital Management sold 10,328 Recursion Pharmaceuticals shares in Q2 2026, an estimated $31.7K.
  • Quantinno Capital Management first reported a position in Recursion Pharmaceuticals in Q1 2025 and held it in 4 quarters.
  • Quantinno Capital Management's Recursion Pharmaceuticals position peaked at $222K in Q4 2025.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Quantinno Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.